Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10886183 | Drug Discovery Today | 2005 | 6 Pages |
Abstract
Fragment-based lead discovery (also referred to as needles, shapes, binding elements, seed templates or scaffolds) is a new lead discovery approach in which much lower molecular weight (120-250Da) compounds are screened relative to HTS campaigns. Fragment-based hits are typically weak inhibitors (10μM-mM), and therefore need to be screened at higher concentration using very sensitive biophysical detection techniques such as protein crystallography and NMR as the primary screening techniques, rather than bioassays. Compared with HTS hits, these fragments are simpler, less functionalized compounds with correspondingly lower affinity. However, fragment hits typically possess high 'ligand efficiency' (binding affinity per heavy atom) and so are highly suitable for optimization into clinical candidates with good drug-like properties.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Robin A.E. Carr, Miles Congreve, Christopher W. Murray, David C. Rees,